Trial Profile
The effect of angiotensin II receptor blocker (ARB) or thiazolidinedione (TZD) on adipocytokines and oxidative stress markers (Senri Study II)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2011
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Pioglitazone (Primary)
- Indications Diabetes mellitus; Hypertension
- Focus Pharmacodynamics
- Acronyms Senri Study II
- 09 Nov 2011 New trial record